August 30, 2018
A drug called mogamulizumab significantly improved progression-free survival for patients with cutaneous T-cell lymphoma, according to the results of a clinical trial published in The Lancet Oncology. The findings led to the FDA’s recent approval of the drug. “For patients affected by this debilitating disease, we can now offer a novel and effective treatment […]